<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170532</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00013822</org_study_id>
    <nct_id>NCT02170532</nct_id>
  </id_info>
  <brief_title>Aerosolized Beta-Agonist Isomers in Asthma</brief_title>
  <official_title>Aerosolized Beta-Agonist Isomers in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      Dr. MacIntyre and his colleagues are studying inhaled medications in asthma. There are two
      new medications that have been approved by the United States Food and Drug Administration
      (FDA): levalbuterol and formoterol. Both of these drugs are similar to standard asthma
      bronchodilator drugs but offer theoretical advantages in terms of fewer side effects. There
      are also newer devices to deliver these medications into the lungs: breath actuated
      nebulizers (BANs) and non-static chambers (Aerochamber-max) that can be used with metered
      dose inhalers (MDIs or &quot;puffers&quot;). The purpose of this study is to deliver these new
      medications using several different devices and measuring lung function, heart rate, and
      sensations of breathlessness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be studied on five separate mornings. The duration of the study and frequency
      of the visits will be solely dependant on the subject availability. Each subject will receive
      all 5 treatments in the same order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maximum Forced Expiratory Volume at One Second (FEV1)</measure>
    <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 8 Hour Area-under-the-curve FEV1</measure>
    <time_frame>0 to 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tremor Assessment Measured by a Scale</measure>
    <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
    <description>Tremor assessment will be made on outstretched hands (0 = none, 1+ = fine tremor, barely perceptible, 2+ = obvious tremor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dyspnea Response as Measured by the University of California, San Diego (UCSD) Dyspnea Scale</measure>
    <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>levalbuterol + saline in a breath actuated nebulizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levalbuterol + ipratroprium in a breath actuated nebulizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levalbuterol MDI 2 puffs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levalbuterol metered dose inhaler 2 puffs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levalbuterol MDI + aerochamber max without pause 2 puffs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levalbuterol MDI + aerochamber max without pause 2 puffs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levalbuterol</intervention_name>
    <description>0.5 ml. levalbuterol</description>
    <arm_group_label>levalbuterol + saline in a breath actuated nebulizer</arm_group_label>
    <arm_group_label>levalbuterol + ipratroprium in a breath actuated nebulizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>0.5ml saline</description>
    <arm_group_label>levalbuterol + saline in a breath actuated nebulizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>levalbuterol MDI</intervention_name>
    <arm_group_label>levalbuterol MDI 2 puffs</arm_group_label>
    <arm_group_label>levalbuterol MDI + aerochamber max without pause 2 puffs</arm_group_label>
    <arm_group_label>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>breath actuated nebulizer</intervention_name>
    <arm_group_label>levalbuterol + saline in a breath actuated nebulizer</arm_group_label>
    <arm_group_label>levalbuterol + ipratroprium in a breath actuated nebulizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>aerochamber max</intervention_name>
    <arm_group_label>levalbuterol MDI + aerochamber max without pause 2 puffs</arm_group_label>
    <arm_group_label>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipratroprium</intervention_name>
    <arm_group_label>levalbuterol + ipratroprium in a breath actuated nebulizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable mild to moderate persistent asthma as defined by the National Asthma Education
             and Prevention Program

          -  greater than 18 years of age

          -  requiring bronchodilator therapy either routinely or on a as needed (PRN)basis

          -  stable with respect to respiratory disease and at least four weeks removed from the
             most recent acute exacerbation of the disease

          -  patients may or may not be on inhaled corticosteroids

        Exclusion Criteria:

          -  no unstable cardiovascular symptoms

          -  no unstable angina

          -  must be at least four weeks removed from an acute coronary syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil MacIntyre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <results_first_submitted>July 10, 2014</results_first_submitted>
  <results_first_submitted_qc>July 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <last_update_submitted>August 11, 2014</last_update_submitted>
  <last_update_submitted_qc>August 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>All subjects will receive all 5 treatments on 5 different treatment days. Each subject will receive all 5 treatments in the same order.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects will receive all 5 treatments on 5 different treatment days. Each subject will receive all 5 treatments in the same order.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects will receive all 5 treatments on 5 different treatment days. Each subject will receive all 5 treatments in the same order.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 &amp; older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximum Forced Expiratory Volume at One Second (FEV1)</title>
        <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
        <population>The same 10 subjects received each of the 5 treatments in the same order. Subjects 1-5 were not included in 6 and 8 hour time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Levalbuterol + Saline in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
saline: 0.5ml saline
breath actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol + Ipratroprium in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
breath actuated nebulizer
ipratroprium</description>
          </group>
          <group group_id="O3">
            <title>Levalbuterol Metered Dose Inhaler (MDI) 2 Puffs</title>
            <description>levalbuterol metered dose inhaler (MDI) 2 puffs
levalbuterol MDI</description>
          </group>
          <group group_id="O4">
            <title>Levalbuterol MDI + Aerochamber Max Without Pause 2 Puffs</title>
            <description>levalbuterol metered-dose inhaler (MDI) + aerochamber max without pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
          <group group_id="O5">
            <title>Levalbuterol MDI + Aerochamber Max With 2 Second Pause 2 Puffs</title>
            <description>levalbuterol metered dose inhaler (MDI) + aerochamber max with 2 second pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum Forced Expiratory Volume at One Second (FEV1)</title>
          <population>The same 10 subjects received each of the 5 treatments in the same order. Subjects 1-5 were not included in 6 and 8 hour time points.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="23.19"/>
                    <measurement group_id="O2" value="20" spread="16.55"/>
                    <measurement group_id="O3" value="20" spread="19.85"/>
                    <measurement group_id="O4" value="19" spread="20.64"/>
                    <measurement group_id="O5" value="21" spread="21.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" spread="31.45"/>
                    <measurement group_id="O2" value="23" spread="19.24"/>
                    <measurement group_id="O3" value="19" spread="22.57"/>
                    <measurement group_id="O4" value="20" spread="24.23"/>
                    <measurement group_id="O5" value="24" spread="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="32.23"/>
                    <measurement group_id="O2" value="22" spread="20.64"/>
                    <measurement group_id="O3" value="20" spread="23.02"/>
                    <measurement group_id="O4" value="19" spread="26.25"/>
                    <measurement group_id="O5" value="19" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="29.05"/>
                    <measurement group_id="O2" value="14" spread="18.89"/>
                    <measurement group_id="O3" value="7" spread="18.99"/>
                    <measurement group_id="O4" value="6" spread="16.88"/>
                    <measurement group_id="O5" value="7" spread="18.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="18.9"/>
                    <measurement group_id="O2" value="1" spread="5.23"/>
                    <measurement group_id="O3" value="-5" spread="5.98"/>
                    <measurement group_id="O4" value="1" spread="16.05"/>
                    <measurement group_id="O5" value="-6" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="21.26"/>
                    <measurement group_id="O2" value="9" spread="13.10"/>
                    <measurement group_id="O3" value="-3" spread="7.91"/>
                    <measurement group_id="O4" value="0" spread="15.54"/>
                    <measurement group_id="O5" value="-6" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 8 Hour Area-under-the-curve FEV1</title>
        <time_frame>0 to 8 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levalbuterol + Saline in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
saline: 0.5ml saline
breath actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol + Ipratroprium in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
breath actuated nebulizer
ipratroprium</description>
          </group>
          <group group_id="O3">
            <title>Levalbuterol MDI 2 Puffs</title>
            <description>levalbuterol metered dose inhaler 2 puffs
levalbuterol MDI</description>
          </group>
          <group group_id="O4">
            <title>Levalbuterol MDI + Aerochamber Max Without Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max without pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
          <group group_id="O5">
            <title>Levalbuterol MDI + Aerochamber Max With 2 Second Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 8 Hour Area-under-the-curve FEV1</title>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5450" spread="7039"/>
                    <measurement group_id="O2" value="4729" spread="4275"/>
                    <measurement group_id="O3" value="3893" spread="4949"/>
                    <measurement group_id="O4" value="3805" spread="5253"/>
                    <measurement group_id="O5" value="4195" spread="4795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate</title>
        <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
        <population>Data for this outcome measure is not reported because the data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Levalbuterol + Saline in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
saline: 0.5ml saline
breath actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol + Ipratroprium in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
breath actuated nebulizer
ipratroprium</description>
          </group>
          <group group_id="O3">
            <title>Levalbuterol MDI 2 Puffs</title>
            <description>levalbuterol metered dose inhaler 2 puffs
levalbuterol MDI</description>
          </group>
          <group group_id="O4">
            <title>Levalbuterol MDI + Aerochamber Max Without Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max without pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
          <group group_id="O5">
            <title>Levalbuterol MDI + Aerochamber Max With 2 Second Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate</title>
          <population>Data for this outcome measure is not reported because the data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tremor Assessment Measured by a Scale</title>
        <description>Tremor assessment will be made on outstretched hands (0 = none, 1+ = fine tremor, barely perceptible, 2+ = obvious tremor).</description>
        <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
        <population>Data for this outcome measure is not reported because the data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Levalbuterol + Saline in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
saline: 0.5ml saline
breath actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol + Ipratroprium in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
breath actuated nebulizer
ipratroprium</description>
          </group>
          <group group_id="O3">
            <title>Levalbuterol MDI 2 Puffs</title>
            <description>levalbuterol metered dose inhaler 2 puffs
levalbuterol MDI</description>
          </group>
          <group group_id="O4">
            <title>Levalbuterol MDI + Aerochamber Max Without Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max without pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
          <group group_id="O5">
            <title>Levalbuterol MDI + Aerochamber Max With 2 Second Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tremor Assessment Measured by a Scale</title>
          <description>Tremor assessment will be made on outstretched hands (0 = none, 1+ = fine tremor, barely perceptible, 2+ = obvious tremor).</description>
          <population>Data for this outcome measure is not reported because the data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dyspnea Response as Measured by the University of California, San Diego (UCSD) Dyspnea Scale</title>
        <time_frame>Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment</time_frame>
        <population>Data for this outcome measure is not reported because the data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Levalbuterol + Saline in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
saline: 0.5ml saline
breath actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol + Ipratroprium in a Breath Actuated Nebulizer</title>
            <description>0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
levalbuterol: 0.5 ml. levalbuterol
breath actuated nebulizer
ipratroprium</description>
          </group>
          <group group_id="O3">
            <title>Levalbuterol MDI 2 Puffs</title>
            <description>levalbuterol metered dose inhaler 2 puffs
levalbuterol MDI</description>
          </group>
          <group group_id="O4">
            <title>Levalbuterol MDI + Aerochamber Max Without Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max without pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
          <group group_id="O5">
            <title>Levalbuterol MDI + Aerochamber Max With 2 Second Pause 2 Puffs</title>
            <description>levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
levalbuterol MDI
aerochamber max</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dyspnea Response as Measured by the University of California, San Diego (UCSD) Dyspnea Scale</title>
          <population>Data for this outcome measure is not reported because the data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>All subjects will receive all 5 treatments on 5 different treatment days. Each subject will receive all 5 treatments in the same order.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neil MacIntyre, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>(919) 681-2720</phone>
      <email>macin001@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

